



## Stereotactic Radiosurgery for Brain Tumors

Guest Editors:

**Dr. Dante Amelio**

**Dr. Piera Navarria**

**Dr. Giuseppe Minniti**

Deadline for manuscript  
submissions:

**15 February 2025**

### Message from the Guest Editors

Dear Colleagues,

Stereotactic radiosurgery (SRS) is the use of a high dose of radiation, stereotactically directed to an intracranial region of interest. This allows for non-surgical treatment of intracranial pathologies, which significantly decreases the risk of morbidity.

There are currently a number of different delivery methods of SRS, including linear accelerators, Gamma or Cyber Knife units, and charged particle methods.

Radiosurgery is currently used in the treatment of brain metastases, meningiomas, vestibular schwannomas, sellar and suprasellar lesions, and arteriovenous malformations. Moreover, SRS is widely used to treat functional conditions, such as trigeminal neuralgia and intractable tremor.

Researchers and clinicians employing SRS in the daily practice are invited to submit manuscripts regarding technical as well as clinical issues.

We look forward to receiving your contributions.

Dr. Dante Amelio

Prof. Giuseppe Minniti

Dr. Piera Navarria

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

**Journal Rank:** JCR - Q2 (*Oncology*)

## Contact Us

---

Current Oncology Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currenocol](http://mdpi.com/journal/currenocol)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)